Follow The Filings

RPRX Royalty Pharma PLC

Health Care, filed as ROYALTY PHARMA PLC (SHS CLASS A), Equity As of 2026 Q3 among managers we track Quote on Google Finance, opens in a new tab

Bought by 1 manager in 2026 Q2, sold by 2

  • 1 Owner
  • Max 4.4%
  • $33M
  • 1 reduce

In 2026 Q3 Torray Investment Partners trimmed Royalty Pharma.

Who owns this now

Largest portfolio weights among holders, up to 4.4% (Torray Investment Partners). Not free-float ownership.

  1. Torray Investment Partners Reduce 4.4%

Who owns RPRX

Sorted by value, long equity only, as of 2026 Q3.

History
Torray Investment Partners 4.4%, was 4.6% Reduce −6.2% 564,461 $33M History

1 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by RPRX's executives, directors and 10% owners in the last 12 months, from their Form 4s

All RPRX insider trades
  • None no insider bought on the open market
  • None no sales outside a trading plan
  • $92.8M sold by 5 insiders under 10b5-1 plans
  1. Marshall Urist EVP, Research & Investments
    Planned sale
    $236K 4,126 shares at $57.10 100% of stake
    Traded Oct 5 Filed Oct 5
    ↗
  2. Marshall Urist EVP, Research & Investments
    Planned sale
    $239K 4,126 shares at $57.88 50% of stake
    Traded Sep 28 Filed Sep 30
    ↗
  3. Christopher Hite Chair
    Planned sale
    $5.9M 100,000 shares at $58.53 27% of stake
    Traded Sep 22 Filed Sep 24
    ↗
  4. Christopher Hite Chair
    Planned sale
    $6M 100,000 shares at $59.97 21% of stake
    Traded Aug 18 Filed Aug 19
    ↗
  5. Terrance P. Coyne CFO
    Planned sale
    $646K 11,002 shares at $58.68 100% of stake
    Traded Aug 13 Filed Aug 17
    ↗
  6. Marshall Urist EVP, Research & Investments
    Planned sale
    $508K 9,099 shares at $55.88 100% of stake
    Traded Jul 1 Filed Jul 2
    ↗
  7. Christopher Hite Chair
    Planned sale
    $7.3M 130,000 shares at $56.50
    Traded Jun 30 Filed Jul 2
    ↗
  8. Marshall Urist EVP, Research & Investments
    Planned sale
    $502K 9,098 shares at $55.18 50% of stake
    Traded Jun 24 Filed Jun 25
    ↗
  9. Christopher Hite Chair
    Planned sale
    $8.2M 150,000 shares at $54.40 21% of stake
    Traded Jun 23 Filed Jun 25
    ↗
  10. Terrance P. Coyne CFO
    Planned sale
    $3.5M 64,399 shares at $53.98 100% of stake
    Traded May 26 Filed May 28
    ↗
  11. Marshall Urist EVP, Research & Investments
    Planned sale
    $722K 13,684 shares at $52.75 43% of stake
    Traded May 20 Filed May 21
    ↗
  12. Marshall Urist EVP, Research & Investments
    Planned sale
    $726K 13,684 shares at $53.06 30% of stake
    Traded May 14 Filed May 15
    ↗
  13. Gregory Norden Director
    Planned sale
    $161K 3,045 shares at $53.00 1.6% of stake
    Traded May 14 Filed May 15
    ↗
  14. Terrance P. Coyne CFO
    Planned sale
    $1.7M 34,791 shares at $49.78 46% of stake
    Traded Apr 28 Filed Apr 30
    ↗
  15. Terrance P. Coyne CFO
    Planned sale
    $1.7M 34,791 shares at $48.33 51% of stake
    Traded Apr 1 Filed Apr 2
    ↗

Also filed in the last 12 months, not counted as buying or selling: 29 stock grants, 1 conversion, and 1 gift.

SEC filings

Recent issuer filings from EDGAR, 9 shown.

Filed Form Detail Links
SCHEDULE 13D/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13D/A — Filing Doc
8-K 5.07 Filing Doc
8-K 1.01,2.03,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc

Source: SEC EDGAR submissions, updated 13 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $2.35B $2.26B $2.38B
Net income $1.13B $0.859B $0.771B
Net margin * 48.2% 37.9% 32.4%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $1.27B $1.8B $1.53B
Total non-current assets * $15.11B $16.42B $18.09B
Total assets $16.38B $18.22B $19.62B
Total current liabilities $0.161B $1.25B $0.636B
Total non-current liabilities * $6.14B $6.63B $9.27B
Total equity $10.08B $10.34B $9.71B

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations $2.99B $2.77B $2.49B
Cash from investing -$2.07B -$2.68B -$1.61B
Cash from financing -$2.15B $0.361B -$1.19B
Net change in cash -$1.23B $0.452B -$0.31B

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.